EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 640 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Mapping Cancer Genomic Evolution Offers Insights into Tumor Development March 6, 2020 Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... February 11, 2025 A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability... October 9, 2023 EMA Recommends Extension of Indications for Dostarlimab January 23, 2025 Load more HOT NEWS Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... An Abnormal Baseline Geriatric 8 Screening Tool Score Strongly Associates with... Deaths from Metastatic Melanoma Drop Substantially in the United States
